Type of the Paper (Article)

Molecular Insights of β-Lactamics Resistance *Klebsiella pneumoniae* Isolates with

Focus on Multidrug Resistance and Virulence from Colonization Samples

Lavouisier F.B. Nogueira[#], Marília S. Maia[#], Marco A.F. Clementino[#], Ila F.N. Lima, Jorge L.N.

Rodrigues, Luciana V.C. Fragoso, Glairta S. Costa, Jose Q.S. Filho, Alexandre Havt, Deiziane

V.S. Costa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman, José K. Sousa* and

Aldo A.M. Lima*

# - These authors contributed equally to this work.

* - Corresponding authors.

Abstract: *Klebsiella pneumoniae* is associated with high resistance to antimicrobials and

is common in isolates from colonization and nosocomial infections. This study aims to

develop assays to detect resistance genes belonging to the *bla* family and investigate

metabolic pathways in resistant isolates of *K. pneumoniae*. The genes of the subfamilies

included were: *bla*SHV, *bla*TEM, *bla*NDM, *bla*KPC, *bla*GES, *bla*CTX-M and relevant

variants of the *bla*OXA subfamily. Mass spectrometry data were acquired on the

Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Isolates

from 122 *K. pneumoniae* samples were collected from 04/23/2019 to 05/29/2021. A high

prevalence of resistance to penicillins, cephalosporins and carbapenems was found

among the isolates. The identified genotypic profile showed a high prevalence of genes

belonging to Ambler's classes of beta-lactamases A, B and D. In the metabolomic study,

the N-fructosyl isoleucine metabolite was identified increased in multidrug-resistant

(MDR) strains of *K. pneumoniae* compared to strains susceptible to antimicrobials. In

conclusion, the assays developed were efficient in detecting the main genes of the *bla*

family of resistance in *K. pneumoniae*. The use of the pentose phosphate metabolic

pathway suggests a benfical regulation of bacterial growt, and colonization in MDR *K.*

pneumoniae strains, with may indicate the use of this pathway as a virulence

mechanism in resistant strains.

KEYWORDS: Antimicrobial resistance; multidrug-resistant; β-lactamases; qPCR;

molecular diagnosis; *Klebsiella pneumoniae*.

INTRODUCTION

Bacterial resistance to antimicrobial agents is a global public health problem

that leads to an increase in the cost of treatment, length of stay, morbidity and

mortality of hospitalized patients, especially in intensive care units (ICU).[1,2] In this

sense, understanding the emergency mechanisms of regulation and dissemination of

resistance to antimicrobial agents in the pathogenesis of bacterial colonization and/or

infection can be of critical importance in preventing and controlling this problem.

Klebsiella pneumoniae is a Gram-negative γ-proteobacteria bacteria, belonging to

the *Enterobacteriacae* family, and is generally viewed as an opportunistic

microorganism, carrying several virulence factors and capable of accumulating

resistance genes to various classes of antimicrobials. It is commonly related to cases of

colonization and/or healthcare-associated infections (HAIs), and has been identified as

an etiological agent in pneumonia, urinary tract infections (UTI), soft tissue and

surgical wound infections, bacteremia, and sepsis.[3]

It is estimated that *K. pneumoniae* is responsible for approximately 10% of all

cases of HAIs, and of these, 32.8% are caused by strains resistant to multiple

antimicrobial drugs. However, studies indicate that the rate of isolated strains

presenting resistance to antimicrobials has increased over the years.[4,5]

K. pneumoniae has been associated with the ability to overcome colonization

resistance imposed by the gastrointestinal microbiota[6] and has been reported as an

emerging Multidrug-Resistant microorgananism of emergency priority by the World

Health Organization (WHO) for the development of new therapies.[7] Epidemiological

data have demonstrated that *K. pneumoniae* can translocate from the gastrointestinal

tract to other sterile sites of the same host or other patients through the fecal-oral route.

What makes clear the clinical relevance of this microorganism. [8]

One of the most likely causes of the increasingly frequent emergence of

bacterial strains resistant to one or more antibiotics is the excessive and sometimes

incorrect use of antimicrobials. The relatively long time required to identify the

pathogen by traditional methods, as well as for the results of the antimicrobial

susceptibility test (AST), forces the clinician to use broad-spectrum drugs empirically,

increasing selective pressure, which ends up benefiting pathogens genetically capable

of adapting to the adverse environment.[1,9]

Possible answers to reduce the time needed to obtain a resistance profile, and to

investigate new approaches in treatment, is the development of molecular

methodologies, that can make the identification of resistance faster, and also be more

sensitive than the traditional methodologies.[10] And the investigation of metabolic

differences between sensitive and resistant strains, that can lead to metabolites or

pathways that can be used as targets for the development of new treatments and

strategies for dealing with multidrug-resistant (MDR) microorganisms. [11-12]

Beta-lactams are the class of antimicrobials most affected by resistance in

general, which is conferred in gram-negatives, mainly by the *bla* gene family, this

group of genes encodes enzymes called beta-lactamases, which are capable of

neutralizing the action of beta-lactams through hydrolysis of the beta-lactam ring.[13–15]

In this study it was investigated the phenotype of resistance, the genotypic

profile of the *bla* family of β-lactamases, and the metabolic differences between

sensitive and MDR *K. pneumoniae* strains, isolated from patients admitted to the ICU in

a university hospital in the city of Fortaleza-CE, Brazil.

We aim to develop a molecular assay, capable of identifying all variants of the

most relevant genes of the *bla* family, these being: *bla*SHV, *bla*TEM, *bla*NDM, *bla*KPC,

*bla*GES and *bla*CTX-M. In addition, also was included the most epidemiologically

relevant variants of the *bla*-OXA subfamily. Thus, creating a set of primers capable of

detecting the presence of hundreds of resistance genes with a reduced number of

reactions. Were also investigated the main differences between the metabolites up and

down regulated in sensitive and MDR strains of *K. pneumoniae*, both from the

intracellular medium and the supernatant among themselves and in comparison, with

the control medium.

RESULTS

Selection of bacterial samples. A total of 249 samples of Gram-negative

bacteria resistant to beta lactam antimicrobials were collected from 04/23/2019 to

05/29/2021, those were identified, and the most prevalent microorganism found was

Klebsiella pneumoniae 48.99% (122/249).

Identification of the phenotypic profile of beta-lactams resistance of *K.*

pneumoniae strains. The bacteria isolates included in the study were tested against a

wide range of beta-lactams drugs, and the presence of a high percentage of isolates

resistant to these drugs was verified, which included **Penicillins**: ampicillin/sulbactam

(92.00%) and piperacillin/tazobactam (88.46%), **Cephalosporins**: cefepime (83.02%),

cefoxitin (73.68%), ceftazidime (86.54%), ceftazidime/avibactam (11 .76%), ceftriaxone

(83.02%), cefuroxime (90.38%) and cefuroxime axetil (81.82%) and **Carbapenems**:

ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%), as shown in **Figure**

1.

Figure 1. Prevalence of *K. pneumoniae* isolates resistant to the beta-lactams evaluated

(Penicillins, Cephalosporins and Carbapenems), demonstrating a phenotypic profile of

resistance to multiple beta-lactams drugs, in approximately 70% of the isolates, with

the exception of ceftazidime/avibactam and ertapenem.

Primers design. After selection on the platforms: Comprehensive Antibiotic

Resistance Data-base (CARD) and National Center for Biotecnology and Information

(NCBI, USA), and subsequent compilation and analysis of FASTA sequences, it was

possible to identify consensus sequences common to all sequences available in the

databases for each of the genes included in the study: *bla*SHV (N = 156), *bla*TEM (N =

167), *bla*NDM (N = 27), *bla*KPC (N = 208), *bla*GES (N = 25), and *bla*CTX-M (N = 144).

Except for the *blaOXA* gene, for which the most clinically relevant sequences were used

(N = 203).

The *bla*CTX-M and *bla*OXA genes, due to its diversity and high degree of

genetic variation between homologous sequences, were grouped into clades, and

divided into groups. the *bla*CTX-M gene group was named according to the

international standardization for this gene with the CTX-M 1*like* been divided into two

groups due to its high number or sequences and the genetic variation between them.

CTX-M 1.1*like* (N = 42), CTX-M 1.2*like* (N = 16), CTX-M 2*like* (N = 23), CTX-M 8*like* (N =

14) and CTX-M 9*like* (N = 49), while the *blaOXA* gene was divided into the OXA-*23like*

(N = 25), OXA-*24/40like* (N = 8), OXA-*48like* (N = 17) and OXA-*51like* (N = 153), as can

be seen in **Figures 2** and **3**.

Figure 2. Cladogram of the *bla*OXA subfamily showing the most epidemiologically

relevant groups, covered by the primers developed, and the percentage of sequences

identifiable by each primer in comparison with the total number of the *bla*OXA family

(N = 441) at the time of publication of this work.

Figure 3. Cladogram with all sequences from the *bla*CTX-M subfamily divided into groups, illustrating the identifiable sequences, and the percentage of sequences detectable by each primer in comparison with the total number of the *bla*CTX-M family (N = 144) until the time of publication of this work.

A total of 14 pairs of primers were developed, which together have the capacity to detect 929 variants of resistance genes belonging to the *bla* gene family. The primer sequences for genes with conserved and non-conserved sequences can be found in **Tables 1** and **2**, respectively.

Table 1. Primer sequences for conserved genes

Name of gene	Number of variations detectable	Primer name	Sequence	Primer size
*bla*SHV	156	SHV-F	ATTATCTCCCTGTTAGCCACCC	22
		SHV-R	GTTTAATTTGCTCAAGCGGCTG	22
*bla*TEM	167	TEM-F	ACCCAGAAACGCTGGTGAAA	20
		TEM-R	GGGGCGAAAACTCTCAAGGA	20
*bla*NDM	27	NDM-F	GAAGCTGAGCACCGCATTAG	20
		NDM-R	CCATTTGCTGGCCAATCGTC	20
*bla*KPC	208	KPC-F	TCGCGGAACCATTCGCTAAA	20
		KPC-R	GAATGAGCTGCACAGTGGGA	20
*bla*GES	25	GES-F	GCCCAGGAGAGAGATTACGC	20
		GES-R	CTTGACCGACAGAGGCAACT	20

145   **Table 2.** Primer sequences for non-conserved genes, divided into clades.

Name of gene		Number of variations detectable	Primer name	Sequence	Primer size
*bla*CTX-M	*bla*CTX-M 1.1*like*	42	CTXM1.1L-F	GATTGCGGAAAAGCACGTCA	20
			CTXM1.1L-R	TTCATCGCCACGTTATCGCT	20
	*bla*CTX-M 1.2*like*	16	CTXM1.2L-F	CGCCGCTGATTCTGGTCA	18
			CTXM1.2L-R	TGACGATTTTAGCCGCCGAC	20

*bla*CTX-M 2*like*	23	CTXM2L-F	ATGGCGCAGACCCTGAAAAA	20
		CTXM2L-R	CTGCCGGTTTTATCGCCCA	19
*bla*CTX-M 8*like*	14	CTXM8L-F	CGCTCAACACCGCGATCC	18
		CTXM8L-R	ATCCCCGACAACCCACGAT	19
*bla*CTX-M 9*like*	49	CTXM9L-F	CGTGGCTCAAAGGCAATACG	20
		CTXM9L-R	TCTGTTGCGGCTGGGTAAAA	20
*bla*OXA	*bla*OXA-23*like*	24	OXA23L-F	GCTCTAAGCCGCGCAAATAC	20
		OXA23L-R	TGACCTTTTCTCGCCCTTCC	20
	*bla*OXA-24/40*like*	8	OXA24/40L-F	TGCCGATGACCTTGCACATA	20
		OXA24/40L-R	CCATTAGCTTGCTCCACCCA	20
	*bla*OXA-48*like*	17	OXA48L-F	?GGTAGCAAAGGAATGGCAAG	21
		OXA48L-R	GGGCGATCAAGCTATTGGGA	20
	*bla*OXA-51*like*	153	OXA51L-F	GATCGGCCTTGAGCACCATA	20
		OXA51L-R	GCCATAACCAACACGCTTCA	20

147 *In silico* **primers validation.** The parameters obtained for each primer after

148 analysis using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite

149 (SMS): PCR Primer Stats software are available in **Table 3**.

150 **Table 3.** Parameters obtained by *in silico* validation of the developed primers.

Gene	Primer name	Tm (C°)	GC%	Self complementarity	Self 3' complementarity	Produt length
*bla*SHV	SHV-F	59,2	50,0	3	0	70
	SHV-R	59,3	45,4	5	3	
*bla*TEM	TEM-F	60,1	50,0	4	0	110

	TEM-R	59,9	55,0	2	1	
*bla*NDM	NDM-F	59,3	55,0	5	1	86
	NDM-R	60,1	55,0	6	2	
*bla*KPC	KPC-F	60,3	50,0	4	2	128
	KPC-R	60,3	55,0	5	1	
*bla*GES	GES-F	59,9	60,0	3	2	94
	GES-R	59,9	55,0	3	2	
*bla*CTX-M 1.1*like*	CTXM1.1L-F	59,7	50,0	4	1	87
	CTXM1.1L-R	60,1	50,0	4	2	
*bla*CTX-M 1.2*like*	CTXM1.2L-F	60,1	61,1	3	2	90
	CTXM1.2L-R	61,0	55,0	3	3	
*bla*CTX-M 2*like*	CTXM2L-F	60,5	50,0	4	0	155
	CTXM2L-R	60,7	57,8	4	1	
*bla*CTX-M 8*like*	CTXM8L-F	61,5	66,6	4	2	197
	CTXM8L-R	60,9	57,8	3	2	
*bla*CTX-M 9*like*	CTXM9L-F	59,9	55,0	3	2	180
	CTXM9L-R	60,1	50,0	3	0	
*bla*OXA-23*like*	OXA23L-F	60,0	55,0	4	0	129
	OXA23L-R	59,9	55,0	2	0	
*bla*OXA-24/40*like*	OXA24/40L-F	59,7	50,0	4	2	177
	OXA24/40L-R	60,0	55,0	4	0	
*bla*OXA-48*like*	OXA48L-F	59,8	52,3	3	0	183
	OXA48L-R	59,8	55,0	4	0	
*bla*OXA-51*like*	OXA51L-F	59,8	55,0	4	2	199
	OXA51L-R	59,1	50,0	2	1	

Testing, optimization, and standardization of *in vitro* reactions. All primers

were tested using positive controls developed *in house,* and it was possible to verify

that the ideal annealing temperature (Ta) for the developed primer pairs was 61°C,

except for the primer referring to the *bla*NDM gene, for which the ideal Ta was 64°C.

The reactions were then evaluated for their specificity and stability by checking the

Melting temperature (Tm). The melting curves are available in the supplementary

material **Figure S1**.

Efficiency curve It was found that all tested primers presented an efficiency

rate ≥93.21 and ≤101.28%, R^2 ≥0.99, and detection limit between ≈2 and ≈13 copies/µL as

shown in **Table 4**.

Table 4. Results of the efficiency curves of the developed primers.

Gene name	Efficiency (%)	Correlation coefficient (R^2)	Threshold	Detection limit (Copies/µL)	Melting Peak (Tm°C)
*bla*SHV	96,15	0,992	0,60	≈2	86,7
*bla*TEM	95,32	1,000	0,70	≈2	81,5
*bla*NDM	99,90	0,999	0,48	≈2	85,7
*bla*KPC	100,44	0,992	0,24	≈2	85,7
*bla*GES	100,21	0,997	0,27	≈2	81,7
*bla*CTX-M 1.1*like*	95,75	0,999	0,40	≈13	84,3
*bla*CTX-M 1.2*like*	100,82	0,994	0,32	≈13	83,2
*bla*CTX-M 2*like*	98,09	0,998	0,30	≈2	86,4
*bla*CTX-M 8*like*	95,32	1,000	0,10	≈13	88,4
*bla*CTX-M 9*like*	97,82	0,996	0,10	≈2	89,0

*bla***OXA-23***like*	99,51	1,000	0,15	≈2	78,4
*bla***OXA-24/40***like*	101,82	0,988	0,15	≈13	78,7
*bla***OXA-48***like*	93,21	1,000	0,20	≈13	80,29
*bla***OXA-51***like*	95,51	0,993	0,55	≈2	82,0

Identification of the genetic resistance profile of *K. pneumoniae* isolates. The

122 *K. pneumoniae* isolates were tested against the 14 pairs of primers developed, and it

was possible to verify a high prevalence of beta-lactam resistance genes among the

isolates analyzed. The most prevalent genes detected were, respectively: *bla*KPC

(95.90%); *bla*SHV (94.26%); *bla*CTX-M 1.2*like* (88.52%); *bla*CTX-M 2*like* (83.61%); *bla*CTX-

M 1.1*like* (80.33%); *bla*TEM (80.33%); *bla*NDM (33.61%); *bla*OXA-23*like* (28.69%); *bla*GES

(20.49%); *bla*OXA-51*like* (15.57%); *bla*CTX-M 9*like* (13.93%); *bla*CTX-M 8*like* (12.30%);

*bla*OXA-24/40*like* (11.48%) *and bla*OXA-48*like* (3.28%). The results can be seen in **Figure**

4A, grouped according to Ambler's classification.

It is important to note that not all variants of each group of genes analyzed

belong to a single class in the Ambler's classification, such as *bla*TEM and *bla*SHV

genes, where not all variants have activity as extended spectrum beta-lactamases

(ESBL) for example, however, due to the grouping of all sequences in a single primer,

the separation of these sequences into other groups would be impossible, so the

grouping of genes was carried out globally in a way that covered the mains

classification of the subfamily in question.

Through the data obtained by the qPCR reactions developed, it was also

possible to verify that the isolates analyzed during this study had the presence of

several genes belonging to the *bla* family accumulated, with values varying from 3 to

12 of the tested genes, present per isolate, as shown in **Figure 4B**.

Figure 4. **(A)** Prevalence of beta-lactams resistance genes among the analyzed isolates,

grouped according to the Ambler classification. **(B)** The percentage of *K. pneumoniae*

isolates showing accumulation of genes encoding beta-lactamases belonging to the *bla*

family.

Comparisons of metabolomic profiles of *K. pneumoniae* **isolates.** In total, 241

metabolites were identified in positive mode and 116 metabolites identified in negative

mode. Among these, 309 metabolites were identified by combining data from both

acquisition modes (positive and negative) without redundancy. The principal

component analysis (PCAs) and the heatmap analysis between the metabolites in

supernatant of susceptible *K. pneumoniae* versus the control culture medium showed

complete separation of the main vectors of the PCA plots and differential upregulation

or downregulation between the two experimental groups (**Figure 5**). Among these

metabolites, 25 were upregulated or downregulated. Interestingly, metabolites related

to the synthesis of nitrogenous bases, protein synthesis and energy supply to the

bacterial cell are significantly increased in supernatant derived from susceptible *K.*

pneumoniae (**Figures S2, S3 and S4**). Similar findings were detected between MDR *K.*

pneumoniae strains and control culture medium (**Figures S5, S6 and S7**).

Figure 5. Comparison between susceptible *K. pneumoniae* supernatants (Sens) versus

culture media. **(A)** Plot of the principal component analysis (PCAs) and **(B)** the

heatmap of the comparison of metabolites between the supernatant of susceptible *K.*

pneumoniae versus the control culture media.

The principal component analysis (PCAs) and the heatmap analysis of

metabolites in supernatants from *K. pneumoniae* MDR versus susceptible isolates

exhibited complete separation of the main vectors of the PCA plots (**Figure 6A**) and

differences on levels of metabolites (**Figure 6B**). The analysis of deregulated

metabolites between *K. pneumoniae* MDR versus susceptible isolates showed increased

N-fructosyl isoleucine in the MDR *K. pneumoniae* isolates (p< 0.05, **Figure 6C**).

Figure 6. Comparison of supernatants from *K. pneumoniae* MDR versus susceptible

(Sens). **(A)** Plots of the principal component analysis (PCAs) and **(B)** the heatmap of the

comparison of metabolites between the supernatant of *K. pneumoniae* MDR versus

susceptible (Sens). **(C)** Plots of dysregulated metabolites between supernatants of *K.*

pneumoniae MDR and susceptible.

Analysis of the intracellular metabolites of susceptible versus MDR K.

pneumoniae showed differences in the PCAs vectors (**Figure 7A**), heatmap (**Figure 7B**).

and increased N-fructosyl isoleucine levels in the MDR K. pneumoniae isolates (p<0.05,

Figure 7C). **Figure 8** shows the PCAs and heatmap plots of supernatant from sensitive

and MDR K. pneumoniae.

Figure 7. Comparison of Intracellular media of *K. pneumoniae* MDR versus susceptible

(Sens). **(A)** Principal Component Analysis (PCAs) plots and **(B)** Heatmap of the

Intracellular Environment of *K. pneumoniae* MDR and susceptible. **(C)** Plots of

dysregulated metabolites between the intracellular media of *K. pneumoniae* MDR and

susceptible.

Figure 8. Comparison of *K. pneumoniae* Multidrug-Resistant (MDR) supernatants

versus culture media. (A) Principal component analysis (PCAs) plots and (B) Heatmap

of the supernatant of *K. pneumoniae* susceptible and MDR. Observe the separation of

the main vectors of the (PCAs) plots and details of the differences in the heatmap

between the two experimental groups.

DISCUSSION

During the period analyzed in the study, 249 bacterial isolates resistant to two

or more class of antimicrobials used in TSA were identified. Of these resistant isolates,

48.99% (122/249) belonged to the species *Klebsiella pneumoniae,* being this

microorganism the most prevalent among those identified.

This data is consistent with what is seen in Egypt, where when evaluating 186

samples from Cairo hospitals, *K. pneumoniae* was found as the main gram-negative

bacterial agent representing 40.9% (76/186) of the identified microorganisms, and

among these isolates obtained, a high prevalence of resistance to beta-lactams,

quinolones, and sulfonamides was identified (89.4%, 89.4% and 87.1%) respectively.[16]

The phenotypic profile of the *K. pneumoniae* isolates analyzed in the present

study demonstrated high levels of resistance to the beta-lactams drugs tested in all

classes evaluated (penicillins, cephalosporins and carbapenems). Although the

resistance profile of strains may vary depending on the test location and the conditions

to prevent spread, the resistance to beta-lactams among *Enterobacteriaceae* is known to

be high, as demonstrated in a study carried out in Brazil, with samples of human and

veterinary origin where 62.85% and 54.28% of *Enterobacteriaceae* isolated were resistant

to amoxicillin/clavulonate and cefazolin respectively.[17]

In studies carried out in Egypt, evaluating isolates of *K. pneumoniae* from food

sources, and in Tunisia and Iran evaluating isolates from hospital samples, the

presence of high resistance to beta-lactams can be verified for ampicillin/sulbactam

(93%), ceftazidime (95.5%), cefoxitin (95.5%), cefotaxime (93.2%),

amoxicillin/clavulonate (86.4%), ertapenem (90.9%) and temocillin (84.0%).[18, 19, 20]

Likewise, in a study carried out with 102 isolates obtained from two Portuguese

hospitals, the presence of resistance rates > 90% was verified for all beta-lactam drugs

tested, except for cephalosporins: cefoxitin (40.2%), cefotetan (68.6%) and carbapenems:

ertapenem (23.5%), imipenem (32.4%), meropenem (34.3%) and doripenem (33.3%).[21]

This result is consistent with that found in this study, where the beta-lactam

drugs that showed a lower resistance rate belonged to the same classes mentioned,

namely: cefoxitin (73.68%), ceftazidime/avibactam (11.76%), ertapenem (44.00%),

imipenem (71.70%) and meropenem (69.81%).

Resistance to beta-lactams is conferred in Gram-negatives mainly by genes

belonging to the *bla* family. This group of genes is composed of dozens of subfamilies

and hundreds of genetic subvariants in each family, the molecular panel developed

managed to encompass some of the most predominant and clinical relevant

subfamilies among clinical isolates, identified in several studies, namely: *bla*SHV,

*bla*TEM, *bla*NDM, *bla*KPC, *bla*GES, *bla*CTX-M and *bla*OXA.[22-24]

After analysis using the Primer-BLAST® (NCBI, USA) and Primer Stats

Sequence Manipulation Suite (SMS) software, it was verified that the developed

primers have specificity for the sequences used in the alignment, melting temperature

(Tm) between 59 29 °C and 61.55 °C, GC% concentration varying between 45.45% and

66.67% in addition to having complementary base numbers ≤ 6 in the analysis of dimer

and hairpin formation. The values obtained for these parameters therefore demonstrate

that they are compatible with those obtained in reference studies.[25-27]

Due to the high number of sequences included in the development of primers,

many of the alternatives obtained through Primer-BLAST® (NCBI, USA) did not meet

the stability requirements regarding the formation of secondary structures (self-

annealing and hairpins), In order to choose the options with the best performance in

relation to these parameters, the GC clamp was relaxed so that the primers SHV-F,

SHV-R, CTXM1.2L-R and CTXM2L-R obtained 4 G or C residues within the last 5

nucleotides of the 3' end, the primers CTXM9L-R and CTXM2L-F did not present C or

G residues within the last 5 nucleotides of the sequence.

This fact could lead to the formation of strong bonds and increase the Tm value

in primers with more than 3 terminal GC residues, and cause inhibition of

amplification due to the presence of weak bonds when there is an absence of terminal

CG [28,29]. Such changes, however, were not evident when the primers were tested *in*

vitro.

The variety of sequences detectable by the developed primers makes in vitro

validation using positive controls for all sequences virtually impossible. In silico

analysis allowed the evaluation of all tested sequences quickly, cheaply and constantly,

since the developed primers can be tested against new variants of the target genes.[26–28]

In vitro analyzes were carried out using SYBR Green master mix, the melting

curve was therefore used as a parameter to evaluate the specificity of the reactions.

And it was verified that for all tested primers a single melting peak was found,

indicating the formation of a single amplicon. And excluding the presence of

secondary structures (primer dimers and hairpins).

The analysis of the melting curve and Tm is considered fundamental to test the

specificity of reactions that use SYBR Green as an amplification indicator, because

unlike reactions that use specific probes, which emit fluorescence only when the

reaction occurs at the expected target. The SYBR Green works by binding to any

double-stranded fragment formed, thus emitting fluorescence. Therefore, only by

analyzing the melting curve and the specific Tm of the amplicon is it possible to

determine whether the reaction was successful.[29–31]

The efficiency curve and its parameters were used to evaluate the performance

of qPCR reactions, by checking how efficiently the targets were amplified in each PCR

cycle.[32, 33] When evaluating the activity of primers in qPCR reactions using the

efficiency curve, it was found that all primers analyzed in this study presented

efficiency values >90% and <110% and correlation coefficients (R^2) >0.9, thus being in

accordance with the parameters presented in reference documents present in the

literature.[33] It was also possible to verify a high detection capacity even at low

concentrations of genetic material since the detection limit obtained varied between ≈2

and ≈13 copies/µL of the target gene used as control.

Several studies report the growth in the prevalence of the *bla*KPC gene, with

this being the most detected carbapenemase worldwide. The values found vary

according to the location. The main variant of the *bla*KPC gene detected is *bla*KPC-2,

with prevalence values varying from 1.2% to 51.6% among enterobacteria in studies

carried out in the United States of America and China respectively.[34, 35] This gene is

found more frequently in isolates of *K. pneumoniae*, many studies report high

prevalence rates in this species ranging from 17.2% to 64.6%.[4, 35, 36, 37]

In a study conducted in an intensive care unit in the northeast reagion of Brazil,

it was shown that of 25 isoates of *K.* pneumoniae obtained during the research, 100%

exhibited the presence of the *bla*KPC gene. [38]

The values found in this paper for the *bla*KPC gene may reflect the fact that the

primer developed detected all variants of the gene, as well as the higher rates of

resistance usually found in intensive care unities (ICU).[39]

The results found in this work are in agreement with other studies performed at

the northeast of Brazil[38], what can represent an endemic presence of the *bla*KPC gene

among *K. pneumoniae* isolates in this Brazilian region.

The *bla*TEM and *bla*SHV genes were the first ESBL identified, and together with

the *bla*CTX-M subfamily of genes are considered the most prevalent ESBL's. These

genes are widely distributed among enterobacteria; in a study carried out in Sudan, the

*bla*TEM, *bla*CTX-M and *bla*SHV genes were identified in 86.0%, 78.0% and 28.0%

respectively.[40]

In a work carried out in ICUs in Chile, it was possible to verify the presence of
these genes with prevalence rates of 81.0%, 84.7% and 73.0% for *bla*SHV, *bla*CTX-M-1
and *bla*TEM, where a higher prevalence of the *bla*SHV gene was found when compared
to the study carried out in Sudan.[41]

In Brazil, it is also possible to verify the presence of high prevalence rates of
these genes among *K.* pneumoniae isolates from ICU, with studies indicating rates of
100%, 96% and 72% for *bla*TEM, *bla*SHV and *bla*CTX-M1 respectively. [38] These results
agree with those evidenced in this study for the K. pneumoniae isolates tested.

The *bla*NDM gene is considered the second most prevalent carbapenemase
producing gene in the world, behind only the *bla*KPC gene. In this study, the presence
of the metallo beta-lactamase NDM gene was verified in (33.61%) of the isolates.
Similar results were evidenced in China, where the presence of this gene was verified
in 35.7% of 935 carbapenem-resistant enterobacteria tested.[34]

The prevalence found in this study for the *bla*NDM gene is still below what was
found in other studies carried out in Brazil in the states of São Paulo and Sergipe,
where the authors found a prevalence of 70 and 50% respectively in *K. pneumoniae*
isolates. [42, 43]

Regarding oxacillinases, a low prevalence of the *bla*OXA-48*like* gene was
observed (3.28%). This gene may be present in all *Enterobacteriaceae*; however, it is more
prevalent in strains of *K. pneumoniae*.[21]

The values found in the literature for the presence of this gene in
Enterobacteriaceae are very divergent, with marked variations related to the location of
the analysis, these values vary from 7.3% in China to 83.3% in Morocco.[34, 44] In a study
conducted in Brazil where 4,451 isolates of *Enterobacteriaceae* were analyzed, the

*bla*OXA-48*like* gene was detected in only 2.5% of the isolates tested.[45] In this way, the

result obtained is compatible with what was previously identified in Brazil, and close

to what is seen in China.

The presence of variants of the *bla*OXA gene (*bla*-OXA-51*like* (15.57%), *bla*OXA-

24/40*like* (11.48%) and *bla*OXA-23*like* (28.69%)) was also observed in the isolates tested,

these genes were long considered exclusive to strains of *Acinetobacter baumannii*,

however studies have demonstrated the presence of these genes in other

Enterobacteriaceae, including *K. pneumoniae*.[46] Results regarding the prevalence of these

genes in strains of *K. pneumoniae* are still scarce, however, in a study conducted in

Bahrain in the Persian Gulf, the *bla*OXA-51 and *bla*OXA-23 genes were identified

respectively in 45.8% and 41.6%. % of *K. pneumoniae* isolates analyzed.[47]

It is believed that many of the beta-lactamases that today can be found

contained in mobile genetic elements had their origin in chromosomes of other

bacteria, as occurred with the SHV type variants that derived from the *K. pneumoniae*

chromosomal SHV-1, and the CTX-M type variants that appear to have originated from

the chromosomal CTX-M of *Kluyvera* spp[21]. This change in the presentation of these

genes, from chromosomal to mobile elements, may explain the appearance of genes

such as chromosomal *bla*OXA present in *A. baumannii* strains on plasmids widespread

in other species.

It was possible to verify the presence of isolates presenting multiple genes

coding for beta-lactamases, from 3 to 12 of the genes analyzed. Studies point to a high

prevalence among *Enterobacteriaceae* of the accumulation of genes from the *bla* family,

mainly genes belonging to ESBL, OXA beta-lactamases and carbapenemases such as

*bla*KPC and *bla*NDM. This phenomenon is more evident in hospital environments

where selective pressure favors microorganisms carrying resistance genes and where

there is a high rate of sharing of these genes.[48,49]

Investigations into metabolomic modulation in *K. pneumoniae* have

demonstrated a promising area for understanding resistance to antimicrobial agents,

developing new therapies, and for studying bacterial virulence. For example,

significant inhibition of the pentose phosphate pathway, citrate cycle, amino acid and

nucleotide metabolism was observed to be beneficial during treatment of MDR *K.*

pneumoniae using the bacteriophage-polymyxin combination, showing the potential for

new therapeutic targets and pathways metabolic processes to improve the effectiveness

of treatment with available antimicrobial agents.[50,51]

This study is in accordance with others that highlighted the importance of the

pentose phosphate pathway in MDR *K. pneumoniae* strains.[50] This finding was present

in both media, supernatant and intracellular in MDR isolates, compared with *K.*

pneumoniae isolates susceptible to antimicrobial agents. The significant presence of the

metabolic N-fructosyl isoleucine ($C_{12}H_{23}NO_7$; MW: 293.316) in the supernatant and

intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose

degradation enzyme gene (*frwC*; fructose-specific phosphotransferase system), which is

involved in regulating bacterial growth, virulence and overcoming colonization

resistance due to the use of alternative carbon source from fructose.[52,53]

Metabolomics has proven to be a promising approach in the study of

antimicrobial resistance. Its use allows for the comprehensive investigation of

metabolic changes associates with different resistance mechanisms, such as alternative

energy-obtaining pathways, modifications that alter the cell wall, communication

between bacterial cells, and changes in the colonization capacity of these microorganisms.[54, 55]

The identification of these metabolic differences plays an important role in the Discovery of new therapeutic targets and strategies for investigating the reversal of resistance in these pathogens.[55-57] The combination of genetic and metabolomic techniques therefore contributes to a comprehensive view of resistance mechanisms in bacteria. [56,57]

The presence of N-fructosyl isoleucine in resistant strains, and the metabolic benefit that its presence appears to generate in increasing colonization capacity, together with the selective pressure found in ICU environments due to the constant use of antimicrobials may be related to the high rates of resistant isolates disseminated among patients in this environment.

The metabolic evaluation in turn points to a metabolic advantage in resistant strains compared to sensitive ones, which goes beyond the resistance capacity itself.[58]

This study has some limitations, such as the exploration of only *bla* family genes, limiting a broader understanding of resistance mechanisms to antimicrobial agents. On the other hand, it presents a broad methodology for exploring the important *bla* family genes most associated with resistance to beta-lactams in *K. pneumonia*. The metabolic findings showed a specific indication that suggests an association with virulence and better proteomic studies will be necessary to associate with potential mechanisms of resistance to antimicrobial agents. Furthermore, additional preclinical studies will be necessary to determine and more specifically validate the virulence associated with the pentose phosphate pathway in *K. pneumoniae*.

CONCLUSIONS

The results of this work show the high prevalence of resistance to antimicrobial agents in isolates of *K. pneumoniae* within the hospital environment, and that this phenotypic pattern exhibited a great concern as it limits the therapeutic options available, directly implicating the patient's prognosis.

The assays developed were within the quality criteria for qPCR reactions using SYBR Green master mix and were efficient in detecting the beta-lactams resistance genes from the *bla* family evaluated in this study. The genotypes of the *bla* genes obtained are relevant and worrying for the local hospital scenario, and compatible with the identified phenotypic profile.

The identification of the metabolic N-fructosyl isoleucine in the supernatant and intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose degradation enzyme gene, which is involved in regulating bacterial growth, virulence and overcoming resistance to colonization due to the use of an alternative carbon source from fructose.

MATERIALS AND METHODS

Obtaining bacterial isolates and identification. For the following study, samples were collected, as part of the clinical investigation of patients admitted to the ICU of a tertiary care health unit in the city of Fortaleza-CE. Were included in the work those microorganisms that were identified as gram-negative bacteria, resistant to two

or more groups of antimicrobial agents, including subclasses of β-lactams,

fluoroquinolones and aminoglycosides.

The bacterial isolates were identified and tested for their susceptibility to

antimicrobials using the automated VITEK® 2 Compact method (BioMérieux, Marcy

l'Etoile, France), according to the manufacturer's recommendations. Minimum

inhibitory concentrations were interpreted according to the Clinical and Laboratory

Standards Institute (CLSI). For quality control of sensitivity tests, strains from the

American Type Culture Collection (ATCC) were used. Specimens that had a resistance

profile that fit the research objectives were included in the study.

Extraction of bacterial DNA. To extract the genetic material, the Wizard

Genomic DNA Purification extraction and purification kit (Promega, Madison, USA)

was used, according to the manufacturer's recommendations.

After extraction, all samples were then quantified by spectrophotometry using

the NanoDropTM 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and

stored in a -80°C freezer until used in the experiments.

Selection of genes used in the study and obtaining FASTA sequences. For

greater coverage of the genetic profile of resistance to β-lactams in gram-negatives,

genes with relevant prevalence epidemiology, belonging to the *bla* gene family, were

part of the study, and these included the genes: *blaSHV, blaTEM, blaNDM, blaKPC,*

blaGES, blaCTX-M and blaOXA. The sequences used were obtained through the

Comprehensive Antibiotic Resistance Database (CARD) and National Center for

Biotecnology information (NCBI) platforms, which compiles and organizes the

resistance gene sequences available in GenBanck, the list of identifiable sequences is

available in the supplementary material Text S1.

Primer design. To design the primers, all variant sequences of each gene

included in the study available on the CARD and NCBI platforms were gathered, the

sequences were aligned using the Clustal Omega software, and the alignments were

analyzed using the SnapGene software.

Consensus regions with homology ≥95% were selected and these were used to

design the primers using the Primer Blast platform from the National Center for

Biotechnology and Information (NCBI, USA). The consensus sequences obtained is

available in the supplementary material Text S2.

Genes with few conserved regions, for which it was not possible to obtain

consensus sequences with homology ≥95%, were separated into clades, and primers

were then designed for the sequences by phylogenetic grouping, complying with a

minimum of 95% similarity.

In silico **validation of the developed primers.** All primers developed were

validated *in silico* regarding their specificity, structure, formation of primer-dimers and

hairpins using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite

(SMS): PCR Primer Stats platforms.

Testing, optimization, and standardization of primers. The reactions were

standardized with the use of positive controls developed in-house, through

amplification of genetic material, isolation, and purification of amplicons, originating

from isolates phenotypically resistant to beta-lactams, and negative control (water

DNase/RNase free). They were carried out using a CYBR Green master mix (Promega,

Madison, USA), the initial results were evaluated regarding the melting temperature

(Tm), to confirm the specificity of the amplicons.

To determine the most efficient qPCR conditions, to reduce the existence of

non-specificity and facilitate the interpretation of the results, the concentration gradient

and annealing temperature (Ta) of the primers were performed. The qPCR reaction

conditions included a hot start step at 95°C for 2 minutes, followed by 35 cycles

consisting of a denaturation step for 15 seconds at 95°C, and an annealing/extension

step for 1 minute at Ta. specific to each primer, all reactions went through a final

melting curve step, with a temperature variation of 60 to 95°C with an increase of

0.05°C/sec.

A 9-point efficiency curve was performed with a dilution factor of 1:8, for each

primer developed, with concentrations ranging from ≈27,438,596 to ≈2 (copies/μL),

through this procedure it was possible to determine the values of threshold, evaluate

the efficiency (%), the correlation coefficient (R^2) and the limit of detection of each

primer.

Detection of resistance-related genes by molecular biology. The *K. pneumoniae*

isolates obtained in the study were tested against the developed primers. Melting

curve analysis of all reactions was used to evaluate the specificity of the results of the

isolates in comparison to the specific melting temperature (Tm) of the positive control.

Preparation of *K. pneumoniae* samples for metabolomic evaluation. Isolates

of *K. pneumoniae* susceptible and multidrug resistant to antimicrobial agents obtained

in this work were submitted for metabolomic analysis. For this experiment, seven

samples of the culture supernatant were designed: one sample of the culture medium,

two samples of the culture supernatant of susceptible *K. pneumoniae* (biological

replicates), four samples of the culture supernatant of multidrug-resistant *K.*

pneumoniae (MDR) for untargeted metabolomics determination and analysis. Samples

of the intracellular medium of the *K. pneumoniae* culture, two samples of susceptible *K.*

pneumoniae (biological replicates) and four samples of MDR *K. pneumoniae* were also

used for untargeted metabolomic analysis. Technical replicates were performed for

susceptible media and samples to allow for a pilot statistical comparison.

Methodology for extracting *K. pneumoniae* culture supernatant. To 200 μL of

K. pneumoniae culture medium or control medium, 800 μL of 80% methanol was added

at -20 °C. The samples were vortexed and incubated at -20°C for 2 hours for protein

precipitation. The samples were centrifuged for 10 min at 4°C at 10,000 g (Benchtop

refrigerated centrifuge 10k RPM Eppendorf) and the supernatants were transferred to

new tubes. The samples were dried under vacuum (Speed Vac Thermo fisher) for

approximately 4-5 hours. Dried samples were redissolved in 100 μL of 0.1% formic

acid in water containing Metabolomics QReSS labeled heavy standards diluted 100X.

(https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf).   A

quality control (QC) was done, combining 10 μL of each sample. After the QC test in

the mass spectrometer, the samples were diluted 10x to be analyzed. The injection

volume of each sample was 10 μL per ionization mode.

Methodology for extractions from the intracellular medium of *K. pneumoniae*

culture. To each tube, 750 μL of cold chloroform:methanol (2:1) mixture at -20 °C was

added, vortexed and transferred to tubes reinforced with a ball beater. Cells were

disrupted in a bead beater with steel balls for 3 min at an intensity of 5 (Bead Ruptor

Elite Omni International Material). The tubes were shaken vigorously for 30 min at 4°C

in a temperature-controlled thermal shaker (Thermomixer Eppendorf). 400 μL of water

was added, shaken vigorously, and centrifuged for 10 min at 10,000 rpm (Benchtop refrigerated centrifuge 10k RPM Eppendorf) for phase separation. The upper aqueous/methanolic phase was saved as a mixture of soluble metabolites and transferred to Eppendorf tubes. Soluble metabolites were dried under vacuum for 3-4 h (Speed Vac Thermo Fisher). Before running, samples were reconstituted in 100 μL of 0.1% formic acid in water containing 100X diluted Metabolomics QReSS labeled heavy standards (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). The QC sample was prepared with 10 μL of each sample. The injection volume of each sample was 10 μL.

Analysis by Ultra Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry (UPLC-MS/MS) of metabolites. MS data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Soluble metabolites were separated using a Waters BEH C18 column (100 x 2.1 mm, 1.9 μm) operated at 30 °C and a flow rate of 250 μL/min. Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in 90% methanol. Bulk scan range: 67-1000 at 120,000 resolutions with 0.6 sec scan range. The 10 most intense ions in each full scan were selected for fragmentation and MS2 spectra were acquired at a resolution of 30,000 and scaled collision dissociation fragmentation energy of 25, 30, 35 was used.

UPLC gradient. The total time used in the UPLC gradient runs was 15 minutes. The flow used was 0.250 mL/min and the following gradient in the percentage of mobile phase B was 50% at 8 min, 98% at 9 min. maintaining until a time of 13 min., ending with 0% between a time of 13.1 – 15 min.

Verification settings in the mass spectrum. The configurations used in the

verification through the mass spectrum were orbit trap of the mass spectrum in the

master scan, with an orbitrap detector with a resolution of 120,000. We used

quadrupole isolation with a scanning range between 67-1000 m/z, using the frequency

lens at 60%. The automatic gain control target was customized and normalized to 25%.

The maximum injection time mode has been customized with a maximum injection

time of 50 ms. MIcroscans of 1 and profile with positive polarity. Font fragmentation

has been disabled.

Data acquisition, metabolic identification, and data analysis. Once the data

was acquired, the samples were analyzed using the open-source software MS-DIAL.

More details about the software can be obtained here:

http://prime.psc.riken.jp/compms/msdial/main.html.[59,60] Three blank samples were

included in the analysis to identify background ions and remove them later. Samples

acquired using MS1 full scan used for quantification and data-dependent acquisition

(DDA) mode were used for spectral identification of metabolites. Tolerance MS1 was

set to 0.01 Da and MS2 set to 0.025 Da. For peak harvesting, the mass slice width was

set to 0.1. For peak alignment, the maximum retention time tolerance was set at 0.5

min, the MS1 tolerance was set at 0.01. Peaks were identified by searching MS2 spectra

in the public MS-DIAL database downloaded in January 2023 (324,191 records for

positive mode and 64,669 entries for negative mode) using a mass tolerance of 0.01 Da

for MS1 and 0.05 Gives to MSMS with an identification cutoff point of 80%

http://prime.psc.riken.jp/compms/msdial/main.html#MSP. Additionally, peaks were

also searched against the core Biomolecular Analysis Facility's internal IROA library

(both positive and negative mode) with a mass tolerance of 0.02 and identification

cutoff of 85%. The data was manually inspected and identifications without MS2 were

filtered, except for identifications of the IROA molecule.

Supplementary Materials: The following supporting information: Figures S1-S7; Text

S1; Text S2.

Figure supplement legend:

Figure S1 – Primer's specificity evaluation through Melting curve: (A) SHV, (B)

KPC, (C) NDM, (D) TEM, (E) GES, (F) OXA-23*like*, (G) OXA-24/40like, (H) OXA-48like,

(I) OXA-51like, (J) CTX-M 1.1*like*, (K) CTX-M 1.2*like*, (L) CTX-M 2*like*, (M) CTX-M 8*like* e

(N) CTX-M 9*like*.

Figure S2 - Plot analysis of the 25 main metabolites from the supernatant of

susceptible *K. pneumoniae* in general without separation by up- or down-regulation of

the analytes. Note that in the supernatant of *K. pneumoniae* compared to the culture

media, metabolites related to the synthesis of nitrogenous bases, protein synthesis and

energy supply to the bacterial cell are significantly increased.

Figure S3 - Plot of the analysis of the 25 main metabolites from the supernatant

of susceptible *K. pneumoniae*, separated because they were up-regulated in relation to

the control culture media.

Figure S4 - Plot of the analysis of the 25 main metabolites from the supernatant

of susceptible *K. pneumoniae*, separated because they were down-regulated in relation

to the control culture media.

Figure S5 - Plot of the analyzes of the 25 main metabolites from the supernatant

of Multidrug-Resistant (MDR) *K. pneumoniae* in general without separation by up- or

down-regulation in the analytes. Note that in the intracellular media of *K. pneumoniae*

compared to the culture medium, metabolites related to the synthesis of nitrogenous

bases, protein synthesis and energy supply to the bacterial cell are significantly

increased.

Figure S6 - Plot of the analysis of the 25 main metabolites from the supernatant

of *K. pneumoniae* MDR, separated by being up-regulated in relation to the control

culture media.

Figure S7 - Plot d of the analysis of the 25 main metabolites from the

supernatant of *K. pneumoniae* MDR, separated because they were down-regulated in

relation to the control culture media.

AUTHOR INFORMATION

Corresponding Authors:

Aldo A.M. Lima - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department

of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

https://orcid.org/0000-0002-0299-1747

Email: alima@ufc.br

José Kleybson de Sousa – Department of Pediatrics Gastroenterology, UVA Hospital,

University of Virginia, Charlottesville, Virginia 22903, United States;

https://orcid.org/0000-0003-3512-484X

Email: ztx7ex@virginia.edu;

Authors

Lavouisier F.B. Nogueira - Institute of Biomedicine, Faculty of Medicine, Federal University

of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program,

Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

https://orcid.org/0000-0002-5008-8181

Marília S. Maia - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department

of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

https://orcid.org/0000-0002-7005-7841

Marco A.F Clementino - Institute of Biomedicine, Faculty of Medicine, Federal University of

Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program,

Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

https://orcid.org/0000-0002-0628-8047

Ila F.N. Lima – Hospital Universitário Walter Cantídio, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil.

Jorge L.N. Rodrigues - Hospital Universitário Walter Cantídio, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil.

Luciana V.C. Fragoso - Hospital Universitário Walter Cantídio, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil.

Glairta S. Costa - Hospital Universitário Walter Cantídio, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil.

Jose Q.S. Filho - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-9619-4553

Alexandre Havt - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,

Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department

of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

https://orcid.org/0000-0002-4546-2976

Deiziane V.S. Costa - Infectious Diseases and International Health, University of Virginia,

Charlottesvillle, VA 22908. https://orcid.org/0000-0001-6402-8908

Lyvia M.V.C. Magalhães - Institute of Biomedicine, Faculty of Medicine, Federal University

of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0001-6990-4903

Dilza Silva - Biomolecular Analysis Facility, School of Medicine, University of Virginia,

Charlottesvillle, VA 22908. https://orcid.org/0000-0002-6519-346X

Nicholas E. Sherman - Biomolecular Analysis Facility, School of Medicine, University of

Virginia, Charlottesvillle, VA 22908. https://orcid.org/0000-0003-3206-3113

Author Contributions:

•   Bibliographic review and data collection, Lavouisier F.B. Nogueira, Marília S.

Maia, Marco A.F Clementino and Aldo A.M. Lima.

- <u>Methodology</u>, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N. Rodrigues, Luciana V. C. Fragoso and Aldo A. M. Lima.

- <u>Bioinformatics</u>, Lavouisier F.B. Nogueira and Marco A.F Clementino.

- <u>In silico analyses</u>, Lavouisier F.B. Nogueira, Marco A.F Clementino.

- <u>*In vitro* validation of primers and sample testing</u>, Lavouisier F.B. Nogueira, Marília S. Maia.

- <u>Metabolomics, Datascience and data Bank</u>, Jose Q.S. Filho; Deiziane V.S. Costa, José K. Sousa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman and Aldo A.M. Lima

- <u>Written review and editing</u>, Lavouisier F.B. Nogueira.

- <u>Supervision</u>, Alexandre Havt and Aldo A.M. Lima.

- <u>Project administration</u>, Aldo A.M. Lima.

- <u>Resource acquisition</u>, Aldo A.M. Lima.

Funding: This research was funded by CNPq (http://www.cnpq.br), grant numbers 402607/2018-0 and 408549/2022-0 and FUNCAP (https://www.funcap.ce.gov.br/), grant number: OFÍCIO Nº 102/2021 – DINOV.

Acknowledge: This work used the following equipments (Benchtop refrigerated centrifuge 10k RPM Eppendorf; Speed Vac Thermo fisher; Bead Ruptor Elite Omni International Material; Thermomixer Eppendorf; Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system) avaliable in the Biomolecular Analysis Core Facility which is supported by the University of Virginia School of Medicine, Research Resource Identifiers (RRID):SCR_025476.

Data Availability Statement: The data and reports relating to this study will be available via direct request via email to the corresponding author.

Conflicts of Interest: The authors declare that there are no financial or personal conflicts of interest that may have influenced the work.

REFERENCES

(1)   Munita, J. M.; Arias, C. A. Mechanisms of Antibiotic Resistance. *Microbiol Spectr* **2016**, *4* (2). https://doi.org/10.1128/MICROBIOLSPEC.VMBF-0016-2015.

(2)   Frieri, M.; Kumar, K.; Boutin, A. Antibiotic Resistance. *J Infect Public Health* **2017**, *10* (4), 369–378. https://doi.org/10.1016/J.JIPH.2016.08.007.

(3)   Holt, K. E.; Wertheim, H.; Zadoks, R. N.; Baker, S.; Whitehouse, C. A.; Dance, D.; Jenney, A.; Connor, T. R.; Hsu, L. Y.; Severin, J.; Brisse, S.; Cao, H.; Wilksch, J.; Gorrie, C.; Schultz, M. B.; Edwards, D. J.; Van Nguyen, K.; Nguyen, T. V.; Dao, T. T.; Mensink, M.; Le Minh, V.; Nhu, N. T. K.; Schultsz, C.; Kuntaman, K.; Newton, P. N.; Moore, C. E.; Strugnell, R. A.; Thomson, N. R. Genomic Analysis of Diversity, Population Structure, Virulence, and Antimicrobial Resistance in Klebsiella Pneumoniae, an Urgent Threat to Public Health. *Proc Natl Acad Sci U S A* **2015**, *112* (27), E3574–E3581. https://doi.org/10.1073/PNAS.1501049112/SUPPL_FILE/PNAS.1501049112.SD01.XLSX.

(4)   Asri, N. A. M.; Ahmad, S.; Mohamud, R.; Hanafi, N. M.; Zaidi, N. F. M.; Irekeola, A. A.; Shueb, R. H.; Yee, L. C.; Noor, N. M.; Mustafa, F. H.; Yean, C. Y.; Yusof, N. Y. Global Prevalence of Nosocomial Multidrug-Resistant Klebsiella Pneumoniae: A Systematic Review and Meta-Analysis. *Antibiotics* **2021**, *10* (12). https://doi.org/10.3390/ANTIBIOTICS10121508.

(5)   Sharma, A.; Thakur, A.; Thakur, N.; Kumar, V.; Chauhan, A.; Bhardwaj, N. Changing
Trend in the Antibiotic Resistance Pattern of Klebsiella Pneumonia Isolated From
Endotracheal Aspirate Samples of ICU Patients of a Tertiary Care Hospital in North
India. *Cureus* **2023**, *15* (3). https://doi.org/10.7759/CUREUS.36317.

(6)   Cortés, G.; Borrell, N.; De Astorza, B.; Gómez, C.; Sauleda, J.; Albertí, S. Molecular
Analysis of the Contribution of the Capsular Polysaccharide and the Lipopolysaccharide
O Side Chain to the Virulence of Klebsiella Pneumoniae in a Murine Model of
Pneumonia. *Infect Immun* **2002**, *70* (5), 2583–2590. https://doi.org/10.1128/IAI.70.5.2583-
2590.2002/FORMAT/EPUB.

(7)   Struve, C.; Bojer, M.; Krogfelt, K. A. Identification of a Conserved Chromosomal Region
Encoding Klebsiella Pneumoniae Type 1 and Type 3 Fimbriae and Assessment of the Role
of   Fimbriae   in   Pathogenicity.   *Infect   Immun*   **2009**,   *77*   (11),   5016–5024.
https://doi.org/10.1128/IAI.00585-09/FORMAT/EPUB.

(8)   Lin, C. T.; Chen, Y. C.; Jinn, T. R.; Wu, C. C.; Hong, Y. M.; Wu, W. H. Role of the CAMP-
Dependent Carbon Catabolite Repression in Capsular Polysaccharide Biosynthesis in
Klebsiella   Pneumoniae.   *PLoS   One*   **2013**,   *8*   (2),   e54430.
https://doi.org/10.1371/JOURNAL.PONE.0054430.

(9)   Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance. *Microbiol Mol Biol*
Rev **2010**, *74* (3), 417. https://doi.org/10.1128/MMBR.00016-10.

(10) Salipante, S. J.; Jerome, K. R. Digital PCR-An Emerging Technology with Broad
Applications   in   Microbiology.   *Clin   Chem*   **2020**,   *66*   (1),   117–123.
https://doi.org/10.1373/CLINCHEM.2019.304048.

(11) Fortuin, S.; Soares, N. C. The Integration of Proteomics and Metabolomics Data Paving
the Way for a Better Understanding of the Mechanisms Underlying Microbial Acquired
Drug Resistance. Frontiers in Medicine 2022, 9. https://doi.org/10.3389/fmed.2022.849838.

(12)   Zeng, C.; Tandhanskul, A.; Krungkaew, S.; Likhanapaiboon, T.; Kasayapanan, W.;

Yasurin, P.; Tang, J.; Phusantisampan, T.; Tawai, A. Research Progress on Using Omics

Technology to Examine the Antimicrobial Mechanisms of Natural Active Substances.

Applied Science and Engineering Progress 2024.

https://doi.org/10.14416/j.asep.2024.07.003.

(13)   Bush, K.; Bradford, P. A. β-Lactams and β-Lactamase Inhibitors: An Overview. *Cold*

Spring Harb Perspect Med **2016**, *6* (8). https://doi.org/10.1101/CSHPERSPECT.A025247.

(14)   Ferreira, A. M.; Martins, K. B.; Silva, V. R. da; Mondelli, A. L.; Cunha, M. de L. R. de S. da.

Correlation of Phenotypic Tests with the Presence of the BlaZ Gene for Detection of Beta-

Lactamase. *Braz J Microbiol* **2017**, *48* (1), 159–166.

https://doi.org/10.1016/J.BJM.2016.10.011.

(15)   Zhu, L. J.; Pan, Y.; Gao, C. Y.; Hou, P. F. Distribution of Carbapenemases and Efflux

Pump in Carbapenem-Resistance Acinetobacter Baumannii. *Ann Clin Lab Sci* **2020**, *50* (2).

(16)   Makharita, R. R.; El-Kholy, I.; Hetta, H. F.; Abdelaziz, M. H.; Hagagy, F. I.; Ahmed, A. A.;

Algammal, A. M. Antibiogram and Genetic Characterization of Carbapenem-Resistant

Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections. *Infect Drug*

Resist **2020**, *13*, 3991–4002. https://doi.org/10.2147/IDR.S276975.

(17)   Santos, A. L.; Dos Santos, A. P.; Ito, C. R. M.; de Queiroz, P. H. P.; de Almeida, J. A.;

Júnior, M. A. B. de C.; de Oliveira, C. Z.; Avelino, M. A. G.; Wastowski, I. J.; Gomes, G. P.

L. A.; E Souza, A. C. S.; Vasconcelos, L. S. N. de O. L.; Santos, M. de O.; da Silva, C. A.;

Carneiro, L. C. Profile of Enterobacteria Resistant to Beta-Lactams. *Antibiotics* **2020**, *9* (7),

1–18. https://doi.org/10.3390/ANTIBIOTICS9070410.

(18)   Abdel-Rhman, S. H. Characterization of β-Lactam Resistance in K. Pneumoniae

Associated with Ready-to-Eat Processed Meat in Egypt. *PLoS One* **2020**, *15* (9), e0238747.

https://doi.org/10.1371/JOURNAL.PONE.0238747.

(19)   Messaoudi, A.; Mansour, W.; Jaidane, N.; Chaouch, C.; Boujaâfar, N.; Bouallègue, O.

Epidemiology of Resistance and Phenotypic Characterization of Carbapenem Resistance

Mechanisms in Klebsiella Pneumoniae Isolates at Sahloul University Hospital-Sousse,

Tunisia. *Afr Health Sci* **2019**, *19* (2), 2008–2020. https://doi.org/10.4314/AHS.V19I2.24.

(20)   Farhadi, M.; Ahanjan, M.; Goli, H. R.; Haghshenas, M. R.; Gholami, M. High Frequency of

Multidrug-Resistant (MDR) Klebsiella Pneumoniae Harboring Several β-Lactamase and

Integron Genes Collected from Several Hospitals in the North of Iran. *Annals of Clinical*

Microbiology and Antimicrobials **2021**, *20* (1). https://doi.org/10.1186/s12941-021-00476-1.

(21)   Oliveira, R.; Castro, J.; Silva, S.; Oliveira, H.; Saavedra, M. J.; Azevedo, N. F.; Almeida, C.

Exploring the Antibiotic Resistance Profile of Clinical Klebsiella Pneumoniae Isolates in

Portugal. *Antibiotics (Basel)* **2022**, *11* (11). https://doi.org/10.3390/ANTIBIOTICS11111613.

(22)   Bush, K.; Bradford, P. A. Epidemiology of β-Lactamase-Producing Pathogens. *Clin*

Microbiol Rev **2020**, *33* (2). https://doi.org/10.1128/CMR.00047-19.

(23)   Castanheira, M.; Simner, P. J.; Bradford, P. A. Extended-Spectrum β-Lactamases: An

Update on Their Characteristics, Epidemiology and Detection. *JAC Antimicrob Resist* **2021**,

3 (3). https://doi.org/10.1093/JACAMR/DLAB092.

(24)   Gundran, R. S.; Cardenio, P. A.; Villanueva, M. A.; Sison, F. B.; Benigno, C. C.;

Kreausukon, K.; Pichpol, D.; Punyapornwithaya, V. Prevalence and Distribution of

BlaCTX-M, BlaSHV, BlaTEM Genes in Extended- Spectrum β- Lactamase- Producing E.

Coli Isolates from Broiler Farms in the Philippines. *BMC Vet Res* **2019**, *15* (1).

https://doi.org/10.1186/S12917-019-1975-9.

(25)   Queiroz, J. A. da S.; Alves, L. S.; Dall'acqua, D. S. V.; Souza, L. F. B.; Faculdades

Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Faculdades Integradas Aparício

Carvalho. Porto Velho, R. Brasil.; Fundação Oswaldo Cruz. Porto Velho, R. Brasil. / F. I.

A. Carvalho. P. V. R. Brasil.; Faculdades Integradas Aparício Carvalho. Porto Velho, R.

Brasil. Desenho e Validação de Primers In Silico Para Detecção Do Vírus Sincicial

Respiratório Humano. *Revista FIMCA* **2017**, *4* (1), 17–30.

(26) Kumar, A.; Chordia, N. In Silico PCR Primer Designing and Validation. *Methods Mol Biol*

2015, *1275*, 143–151. https://doi.org/10.1007/978-1-4939-2365-6_10.

(27) Rodríguez, A.; Rodríguez, M.; Córdoba, J. J.; Andrade, M. J. Design of Primers and Probes

for Quantitative Real-Time PCR Methods. *Methods in Molecular Biology* **2015**, *1275*, 31–56.

https://doi.org/10.1007/978-1-4939-2365-6_3.

(28) van Weezep, E.; Kooi, E. A.; van Rijn, P. A. PCR Diagnostics: In Silico Validation by an

Automated Tool Using Freely Available Software Programs. *J Virol Methods* **2019**, *270*,

106–112. https://doi.org/10.1016/J.JVIROMET.2019.05.002.

(29) Yang, J.; Kemps-Mols, B.; Spruyt-Gerritse, M.; Anholts, J.; Claas, F.; Eikmans, M. The

Source of SYBR Green Master Mix Determines Outcome of Nucleic Acid Amplification

Reactions. *BMC Res Notes* **2016**, *9* (1), 1–10. https://doi.org/10.1186/S13104-016-2093-

4/FIGURES/4.

(30) Wang, Y.; Li, W.; Guo, X.; Zhang, D.; Sun, J.; Fu, Z.; Liu, G.; Li, Y.; Jiang, S. Development

of SYBR Green I-Based Polymerase Chain Reaction for Feline Bocavirus 1 Detection. *3*

Biotech **2021**, *11* (2). https://doi.org/10.1007/S13205-020-02577-8.

(31) Desriani; Azamris; Ghaissani, S. S.; Kinanti, S. R.; Warisman, M. A.; Fitria, N. Design and

Characterization of a SYBR Green I-Based Melting Curve Method for Investigation of

HER2I655V Polymorphism in Breast Cancer. *J Genet Eng Biotechnol* **2021**, *19* (1).

https://doi.org/10.1186/S43141-020-00108-9.

(32) Svec, D.; Tichopad, A.; Novosadova, V.; Pfaffl, M. W.; Kubista, M. How Good Is a PCR

Efficiency Estimate: Recommendations for Precise and Robust QPCR Efficiency

Assessments. *Biomol Detect Quantif* **2015**, *3*, 9–16.

https://doi.org/10.1016/J.BDQ.2015.01.005.

(33)   Thermo Fisher Scientific. *Real-Time PCR: Understanding Ct - US*.

https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-

learning-center/real-time-pcr-basics/real-time-pcr-understanding-ct.html (accessed 2024-

05-05).

(34)   Han, R.; Shi, Q.; Wu, S.; Yin, D.; Peng, M.; Dong, D.; Zheng, Y.; Guo, Y.; Zhang, R.; Hu, F.

Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among

Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in

China. *Front Cell Infect Microbiol* **2020**, *10*, 314. https://doi.org/10.3389/FCIMB.2020.00314.

(35)   Marschall, J.; Tibbetts, R. J.; Dunne, W. M.; Frye, J. G.; Fraser, V. J.; Warren, D. K. Presence

of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its

Correlation with In Vitro Carbapenem Susceptibility. *J Clin Microbiol* **2009**, *47* (1), 239.

https://doi.org/10.1128/JCM.02123-08.

(36)   Kharazmkia, A.; Amirizadeh, M.; Goudarzi, Z.; Birjandi, M.; Barfipoursalar, A.; Mir, S.

Prevalence of KPC-Producing Bacteria in Negative Gram of Clinical Samples Obtained

from Patients. *Annals of Medicine and Surgery* **2022**, *77*, 103690.

https://doi.org/10.1016/J.AMSU.2022.103690.

(37)   Pawłowska, I.; Ziółkowski, G.; Jachowicz-Matczak, E.; Stasiowski, M.; Gajda, M.;

Wójkowska-Mach, J. Colonization and Healthcare-Associated Infection of Carbapenem-

Resistant Enterobacteriaceae, Data from Polish Hospital with High Incidence of

Carbapenem-Resistant Enterobacteriaceae, Does Active Target Screening Matter?

Microorganisms **2023**, *11* (2). https://doi.org/10.3390/MICROORGANISMS11020437.

(38)   Ferreira, R. L.; da Silva, B. C. M.; Rezende, G. S.; Nakamura-Silva, R.; Pitondo-Silva, A.;

Campanini, E. B.; Brito, M. C. A.; da Silva, E. M. L.; Freire, C. C. de M.; Cunha, A. F. da;

Pranchevicius, M.-C. da S. High Prevalence of Multidrug-Resistant Klebsiella

Pneumoniae Harboring Several Virulence and β-Lactamase Encoding Genes in a

859   Brazilian  Intensive  Care  Unit. *Frontiers in Microbiology* **2019**, *9*.

860   https://doi.org/10.3389/fmicb.2018.03198.

861 (39) Kernéis, S.; Lucet, J. C.; Santoro, A.; Meschiari, M. Individual and Collective Impact of

862   Klebsiella Pneumoniae Carbapenemase (KPC)-Producing K. Pneumoniae in Patients

863   Admitted to the ICU. *J Antimicrob Chemother* **2021**, *76* (Suppl 1), I19–I26.

864   https://doi.org/10.1093/JAC/DKAA494.

865 (40) Dirar, M. H.; Bilal, N. E.; Ibrahim, M. E.; Hamid, M. E. Prevalence of Extended-Spectrum

866   β-Lactamase (ESBL) and Molecular Detection of Bla TEM, Bla SHV and Bla CTX-M

867   Genotypes among Enterobacteriaceae Isolates from Patients in Khartoum, Sudan. *Pan Afr*

868   *Med J* **2020**, *37*, 1–11. https://doi.org/10.11604/PAMJ.2020.37.213.24988.

869 (41) Pavez, M.; Troncoso, C.; Osses, I.; Salazar, R.; Illesca, V.; Reydet, P.; Rodríguez, C.;

870   Chahin, C.; Concha, C.; Barrientos, L. High Prevalence of CTX-M-1 Group in ESBL-

871   Producing Enterobacteriaceae Infection in Intensive Care Units in Southern Chile. *Braz J*

872   *Infect Dis* **2019**, *23* (2), 102–110. https://doi.org/10.1016/J.BJID.2019.03.002.

873 (42) Camargo, C. H.; Yamada, A. Y.; Souza, A. R. de; Reis, A. D.; Santos, M. B. N.; Assis, D. B.

874   de; Carvalho, E. de; Takagi, E. H.; Cunha, M. P. V.; Tiba-Casas, M. R. Genomic Diversity

875   of NDM-Producing Klebsiella Species from Brazil, 2013–2022. Antibiotics 2022, 11 (10),

876   1395.https://doi.org/10.3390/antibiotics11101395.

877 (43) Vivas, R.; Dolabella, S. S.; Barbosa, A. A. T.; Jain, S. Prevalence of Klebsiella Pneumoniae

878   Carbapenemase - and New Delhi Metallo-Beta-Lactamase-Positive K. Pneumoniae in

879   Sergipe, Brazil, and Combination Therapy as a Potential Treatment Option. *Revista da*

880   *Sociedade Brasileira de Medicina Tropical* **2020**, *53*. https://doi.org/10.1590/0037-8682-0064-

881   2020.

882 (44) Belouad, E. M.; Benaissa, E.; El Mrimar, N.; Bssaibis, F.; Maleb, A.; Elouennass, M.

883   Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan

884   Hospital. *Int J Microbiol* **2023**, *2023*. https://doi.org/10.1155/2023/8581883.

(45) Magagnin, C. M.; Rozales, F. P.; Antochevis, L.; Nunes, L. S.; Martins, A. S.; Barth, A. L.;

Sampaio, J. M.; Zavascki, A. P. Dissemination of Bla OXA-370 Gene among Several

Enterobacteriaceae Species in Brazil. *Eur J Clin Microbiol Infect Dis* **2017**, *36* (10), 1907–

1910. https://doi.org/10.1007/S10096-017-3012-X.

(46) Evans, B. A.; Amyes, S. G. B. OXA β-Lactamases. *Clin Microbiol Rev* **2014**, *27* (2), 241–263.

https://doi.org/10.1128/CMR.00117-13/ASSET/DF7BB1F6-F6E8-4208-8829-

B01CD28A0242/ASSETS/GRAPHIC/ZCM9990924610006.JPEG.

(47) Shahid, M.; Ahmad, N.; Saeed, N. K.; Shadab, M.; Joji, R. M.; Al-Mahmeed, A.; Bindayna,

K. M.; Tabbara, K. S.; Dar, F. K. Clinical Carbapenem-Resistant Klebsiella Pneumoniae

Isolates Simultaneously Harboring Bla NDM-1, Bla OXA Types and QnrS Genes from the

Kingdom of Bahrain: Resistance Profile and Genetic Environment. *Front Cell Infect*

Microbiol **2022**, *12*. https://doi.org/10.3389/FCIMB.2022.1033305.

(48) Manandhar, S.; Zellweger, R. M.; Maharjan, N.; Dongol, S.; Prajapati, K. G.; Thwaites, G.;

Basnyat, B.; Dixit, S. M.; Baker, S.; Karkey, A. A High Prevalence of Multi-Drug Resistant

Gram-Negative Bacilli in a Nepali Tertiary Care Hospital and Associated Widespread

Distribution of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-

Encoding Genes. *Ann Clin Microbiol Antimicrob* **2020**, *19* (1), 1–13.

https://doi.org/10.1186/S12941-020-00390-Y/FIGURES/5.

(49) Awosile, B. B.; Agbaje, M.; Adebowale, O.; Kehinde, O.; Omoshaba, E. Beta-Lactamase

Resistance Genes in Enterobacteriaceae from Nigeria. *Afr J Lab Med* **2022**, *11* (1).

https://doi.org/10.4102/AJLM.V11I1.1371.

(50) Han, M. L.; Nang, S. C.; Lin, Y. W.; Zhu, Y.; Yu, H. H.; Wickremasinghe, H.; Barlow, C. K.;

Creek, D. J.; Crawford, S.; Rao, G.; Dai, C.; Barr, J. J.; Chan, K.; Turner Schooley, R.;

Velkov, T.; Li, J. Comparative Metabolomics Revealed Key Pathways Associated with the

Synergistic Killing of Multidrug-Resistant Klebsiella Pneumoniae by a Bacteriophage-

910   Polymyxin Combination. *Comput Struct Biotechnol J* **2022**, *20*, 485–495.

911   https://doi.org/10.1016/J.CSBJ.2021.12.039.

912 (51)   Kumar, A.; Singh, S.; Gupta, S. K.; Kumar, S.; Kumar, S.; Singh, R.; Thakur, L.; Kumar, M.;

913   Kapil, A.; Kumar, Y.; Kumar, N. Identification of Metabolite Extraction Method for

914   Targeted Exploration of Antimicrobial Resistance Associated Metabolites of Klebsiella

915   Pneumoniae. *Sci Rep* **2022**, *12* (1). https://doi.org/10.1038/S41598-022-12153-0.

916 (52)   Hudson, A. W.; Barnes, A. J.; Bray, A. S.; Ornelles, D. A.; Zafar, M. A. Klebsiella

917   Pneumoniae L-Fucose Metabolism Promotes Gastrointestinal Colonization and

918   Modulates Its Virulence Determinants. *Infect Immun* **2022**, *90* (10).

919   https://doi.org/10.1128/IAI.00206-22.

920 (53)   Lin, D.; Fan, J. M.; Wang, J.; Liu, L.; Xu, L.; Li, F.; Yang, J.; Li, B. The Fructose-Specific

921   Phosphotransferase System of Klebsiella Pneumoniae Is Regulated by Global Regulator

922   CRP and Linked to Virulence and Growth. *Infect Immun* **2018**, *86* (8).

923   https://doi.org/10.1128/IAI.00340-18.

924 (54)   Aminov, R. Metabolomics in Antimicrobial Drug Discovery. *Expert Opinion on Drug*

925   *Discovery* **2022**, *17* (9), 1047–1059. https://doi.org/10.1080/17460441.2022.2113774.

926 (55)   Kok, M.; Maton, L.; van der Peet, M.; Hankemeier, T.; van Hasselt, J. G. C. Unraveling

927   Antimicrobial Resistance Using Metabolomics. *Drug Discovery Today* **2022**, *27* (6), 1774–

928   1783. https://doi.org/10.1016/j.drudis.2022.03.015.

929 (56)   Soni, V.; Wang, Z.; Singh, V. Editorial: Bacterial Metabolomics Approach towards

930   Antimicrobials and Resistance. *Frontiers in Microbiology* **2023**, *14*.

931   https://doi.org/10.3389/fmicb.2023.1222594.

932 (57)   Abril, A. G.; Quintela-Baluja, M.; Villa, T. G.; Calo-Mata, P.; Barros-Velázquez, J.; Carrera,

933   M. Proteomic Characterization of Virulence Factors and Related Proteins in Enterococcus

934   Strains from Dairy and Fermented Food Products. International Journal of Molecular

935   Sciences 2022, 23 (18), 10971. https://doi.org/10.3390/ijms231810971.

936   (58)   Azhar, F.; Busharat, M.; Chaudhary, S. R.; Waheed, Z.; Jamil, M. Metabolomics in Drug

937   Discovery: Restoring Antibiotic Pipeline. *Asian Pacific Journal of Tropical Biomedicine* **2023**,

938   *13* (9), 378. https://doi.org/10.4103/2221-1691.385568.

939   (59)   Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.;

940   Vandergheynst, J.; Fiehn, O.; Arita, M. MS-DIAL: Data-Independent MS/MS

941   Deconvolution for Comprehensive Metabolome Analysis. *Nature Methods 2015 12:6* **2015**,

942   *12* (6), 523–526. https://doi.org/10.1038/nmeth.3393.

943   (60)   Tsugawa, H.; Nakabayashi, R.; Mori, T.; Yamada, Y.; Takahashi, M.; Rai, A.; Sugiyama,

944   R.; Yamamoto, H.; Nakaya, T.; Yamazaki, M.; Kooke, R.; Bac-Molenaar, J. A.; Oztolan-

945   Erol, N.; Keurentjes, J. J. B.; Arita, M.; Saito, K. A Cheminformatics Approach to

946   Characterize Metabolomes in Stable-Isotope-Labeled Organisms. *Nat Methods* **2019**, *16* (4),

947   295–298. https://doi.org/10.1038/S41592-019-0358-2.

948